GLP1R and diabetes mellitus: Coverage for antiobesity medications varies greatly by source of insurance and plan type, and plans may impose step therapy or behavioral modification program requirements.38,39 Approximately 1 in 4 employers report offering coverage for GLP-1 receptor agonists for weight loss indications, while more than three-fourths cover them for diabetes.40,41,42 Future analyses should investigate how plan structures can affect access to antiobesity medications and improve employee awareness of these plan dynamics prior to open enrollment periods.